AxoGen (AXGN)
(Delayed Data from NSDQ)
$11.02 USD
+0.27 (2.51%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $11.04 +0.02 (0.18%) 5:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$11.02 USD
+0.27 (2.51%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $11.04 +0.02 (0.18%) 5:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Zacks News
Here's Why Momentum in AxoGen (AXGN) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Zacks.com featured highlights include AxoGen, Western Digital, Accolade and Credo Technology Group
by Zacks Equity Research
AxoGen, Western Digital, Accolade and Credo Technology Group are part of the Screen of the Week article.
4 Top Stocks That Flaunt Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as AxoGen (AXGN), Western Digital (WDC), Accolade (ACCD) and Credo Technology (CRDO) for superb earnings acceleration.
Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zacks.com featured highlights include Aspen Aerogels, AxoGen and Credo Technology Group
by Zacks Equity Research
Aspen Aerogels, AxoGen and Credo Technology Group are part of the Zacks Screen of the Week article.
3 Stocks Worth a Look for Solid Earnings Acceleration
by Tirthankar Chakraborty
Keep a tab on stocks such as Aspen Aerogels (ASPN), AxoGen (AXGN) and Credo Technology Group (CRDO) for superb earnings acceleration.
Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Dynatronics Corporation (DYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 80% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 500% and 5.69%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 3.51% and 7.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think AxoGen (AXGN) Could Surge 69.62%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for AxoGen (AXGN) points to a 69.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 33.33% and 2.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Si-Bone (SIBN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Si-Bone (SIBN) delivered earnings and revenue surprises of 8.89% and 0.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 550% and 2.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
AxoGen (AXGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
by Zacks Equity Research
Here is how Catalyst Pharmaceutical (CPRX) and AxoGen (AXGN) have performed compared to their sector so far this year.
AxoGen (AXGN) Soars 8.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Wall Street Analysts Think AxoGen (AXGN) Could Surge 89%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 89.4% upside potential for AxoGen (AXGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Are Medical Stocks Lagging Acadia Healthcare (ACHC) This Year?
by Zacks Equity Research
Here is how Acadia Healthcare (ACHC) and AxoGen (AXGN) have performed compared to their sector so far this year.